A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) (clinicaltrials.gov) - Sep 29, 2026 - P1/2 | N=55 | Not yet recruiting | Sponsor: Boehringer Ingelheim
New P1/2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
|